COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin

Breast Cancer Research and Treatment

Volumn 130, Issue 2, 2011, Pages 657-662

  Holmes, Michelle D ^a,c   Chen, Wendy Y ^a,b   Schnitt, Stuart J ^c,d   Collins, Laura ^d   Colditz, Graham A ^e   Hankinson, Susan E ^a,c   Tamimi, Rulla M ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aspirin; Breast neoplasms; Cyclooxygenase 2; Prognosis; Survival; Tumor markers

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2; ESTROGEN RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER INVASION; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; DEATH CERTIFICATE; DISEASE ASSOCIATION; DRUG USE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION;

ADULT; ANTINEOPLASTIC AGENTS; ASPIRIN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CYCLOOXYGENASE 2; FEMALE; HUMANS; LOGISTIC MODELS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 82955212867     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1651-7     Document Type: Article

References (21)

1. Kwan ML, Habel LA, Slattery ML, Caan B (2007) NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control 18(6):613-620. doi:10.1007/s10552-007-9003-y (Pubitemid 46883678)
2. Blair CK, Sweeney C, Anderson KE, Folsom AR (2007) NSAID use and survival after breast cancer diagnosis in post-menopausal women. Breast Cancer Res Treat 101(2):191-197. doi:10.1007 /s10549-006-9277-x (Pubitemid 46115425)
3. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE (2010) Aspirin intake and survival after breast cancer. J Clin Oncol 28:1467-1472. doi:10.1200/JCO.2009. 22.7918
4. Egan KM, Stampfer MJ, Giovannucci E, Rosner BA, Colditz GA (1996) Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst 88(14):988-993 (Pubitemid 26239387)
5. Takkouche B, Regueira-Mendez C, Etminan M (2008) Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 100(20):1439-1447. doi:10.1093/jnci/djn324
6. Chan AT, Ogino S, Fuchs CS (2009) Aspirin use and survival after diagnosis ofcolorectal cancer. JAMA 302(6):649-658. doi: 10.1001/jama.2009.1112
7. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J (2002) Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 62(3):632-635 (Pubitemid 34126931)
8. Zeeneldin AA, Mohamed AM, Abdel HA, Taha FM, Goda IA, Abodeef WT (2009) Survival effects of cyclooxygenase-2 and 12-lipooxygenase in Egyptian women with operable breast can-cer. Indian J Cancer 46(1):54-60
9. Zhang SM, Cook NR, Manson JE, Lee IM, Buring JE (2008) Low-dose aspirin and breast cancer risk: results by tumour characteristics from a randomised trial. Br J Cancer 98(5):989-991. doi:10.1038/sj.bjc.6604240 (Pubitemid 351341601)
10. Nassar A, Radhakrishnan A, Cabrero IA, Cotsonis G, Cohen C (2007) COX-2 expression in invasive breast cancer: correlation with prognostic parameters and outcome. Appl Immunohistochem Mol Morphol 15(3):255-259. doi:10.1097/01.pai. 0000213130. 63417.b3 (Pubitemid 47329915)
11. Park K, Han S, Shin E, Kim HJ, Kim JY (2006) Cox-2 expression on tissue microarray of breast cancer. Eur J Surg Oncol 32(10):1093-1096. doi:10.1016/j.ejso.2006.05.010 (Pubitemid 44774393)
12. Surowiak P, Materna V, Matkowski R, Szczuraszek K, Kornafel J, Wojnar A, Pudelko M, Dietel M, Denkert C, Zabel M, Lage H (2005) Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance. Breast Cancer Res 7(5):R862-R870. doi: 10.1186/bcr1313
13. Kim JH, Bossuyt V, Ponn T, Lannin D, Haffty BG (2005) Cyclooxygenase-2 expression in postmastectomy chest wall relapse. Clin Cancer Res 11(14):5199-5205. doi:10.1158/1078-0432.CCR-05-0524 (Pubitemid 41003707)
14. Denkert C, Winzer KJ, Muller BM, Weichert W, Pest S, Kobel M, Kristiansen G, Reles A, Siegert A, Guski H, Hauptmann S (2003) Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 97(12):2978-2987 (Pubitemid 36676251)
15. Wulfing P, Diallo R, Muller C, Wulfing C, Poremba C, Heinecke A, Rody A, Greb RR, Bocker W, Kiesel L (2003) Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis. J Cancer Res Clin Oncol 129(7):375-382 (Pubitemid 36995136)
16. Costa C, Soares R, Reis-Filho JS, Leitao D, Amendoeira I, Schmitt FC (2002) Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 55(6):429-434 (Pubitemid 34620779)
17. Witton CJ, Hawe SJ, Cooke TG, Bartlett JM (2004) Cyclooxy-genase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology 45(1):47-54 (Pubitemid 38969561)
18. Nakopoulou L, Mylona E, Papadaki I, Kapranou A, Giannop-oulou I, Markaki S, Keramopoulos A (2005) Overexpression of cyclooxygenase-2 is associated with a favorable prognostic phenotype in breast carcinoma. Pathobiology 72(5):241-249. doi: 10.1159/000089418 (Pubitemid 43004467)
19. Spizzo G, Gastl G, Wolf D, Gunsilius E, Steurer M, Fong D, Amberger A, Margreiter R, Obrist P (2003) Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br J Cancer 88(4):574-578 (Pubitemid 36363367)
20. Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L, Fu Y, Deitz AC, Connolly JL, Schnitt SJ, Colditz GA, Collins LC (2008) Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 10(4):R67. doi:10.1186/bcr2128
21. Howe LR, Lippman SM (2008) Modulation ofbreast cancer risk by nonsteroidal anti-inflammatory drugs. J Natl Cancer Inst 100(20):1420-1423. doi:10.1093/jnci/djn347